Humana Inc vs Royal Caribbean Cruises Ltd — how do they compare? Humana Inc trades at $444.61 (market cap $46.49B), while Royal Caribbean Cruises Ltd trades at $282.65 (market cap $75.26B). The key difference: Royal Caribbean Cruises Ltd is the larger of the two by market cap, and Royal Caribbean Cruises Ltd pays the higher dividend (2.13%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Royal Caribbean Cruises Ltd for 85 Days on average.
| HUM | RCL | |
|---|---|---|
Market Cap | $46.49B | $75.26B |
Volume | 2,567,704 | 1,958,628 |
Sector | Health | Consumer Cyclical |
52-Week High | $409.85 | $348.03 |
52-Week Low | $163.67 | $230.30 |
Typical Hold Time | 53 Days | 85 Days |
Enterprise Value | $53.84B | $97.91B |
Dividend Yield | 0.91% | 2.13% |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $441.74, up 11.41% over 24 hours, reflecting strong momentum. The stock shows bullish technical signals with support at $391 and resistance at $406. Fundamentally, revenue grew to $129.66B in 2025, though net income margin compressed to 0.88%. Recent news highlights a Barclays upgrade to a $515 price target and upcoming Q3 earnings on November 6, 2026.
The outlook is cautiously optimistic with a consensus price target of $457.05 implying modest upside. Risks include margin pressure from Medicare Advantage plan changes and potential regulatory scrutiny. Institutional activity is mixed, with Bank of America adding a position while some funds reduced stakes.
Royal Caribbean (RCL) trades at $282.36, down 2.25% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamental performance with Q1 and Q2 2026 earnings beats, revenue growth to $17.93B in 2025, and improving profit margins. Recent developments include a $3B investment in Sandals Resorts, expanding into the all-inclusive resort market. Analyst consensus remains positive with a $346.67 price target and 51% buy ratings.
RCL presents a compelling growth story with strong earnings momentum and strategic expansion, though investors face risks from high leverage, fuel cost volatility, and execution challenges from the Sandals acquisition. The stock's current valuation appears reasonable given growth prospects, but requires monitoring of debt levels and integration success.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →